570,409 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Magellan Asset Management Ltd

Posted by Francis Steltz on Aug 24th, 2026

Magellan Asset Management Ltd bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 570,409 shares of the medical equipment provider’s stock, valued at approximately $49,107,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. DV Equities LLC bought a new stake in Zimmer Biomet in the 4th quarter worth approximately $25,000. Tacita Capital Inc bought a new position in shares of Zimmer Biomet in the second quarter worth approximately $26,000. Monetary Solutions Ltd purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at about $30,000. Gen Wealth Partners Inc purchased a new position in Zimmer Biomet during the 4th quarter valued at about $31,000. Finally, Elevation Wealth Partners LLC raised its holdings in shares of Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Stock Up 0.0%

Shares of Zimmer Biomet stock opened at $101.01 on Monday. The company has a market cap of $19.27 billion, a price-to-earnings ratio of 24.58, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The company’s 50 day moving average is $92.64 and its 200 day moving average is $91.04.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the business earned $2.07 earnings per share. Zimmer Biomet’s revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on ZBH shares. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Canaccord Genuity Group increased their target price on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Zacks Research lowered Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 27th. Wells Fargo & Company reduced their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $104.42.

Get Our Latest Research Report on Zimmer Biomet

About Zimmer Biomet

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.